5 - High
FDA labeling and/or multiple well-designed human randomized trials for the specific use being discussed.
Tool
Research Evidence Grading Guide
A simple scoring system for ranking peptide claims by evidence quality, not popularity.
Featured snippet
How PeptideWars Grades Evidence
PeptideWars gives the most weight to FDA labels and human randomized trials. Animal studies, cell studies, biomarker changes, and anecdotes are treated as early or indirect evidence unless supported by human outcomes.
4 - Strong clinical
Substantial human evidence, often for a narrow indication or population, with important safety and label boundaries.
3 - Moderate
Older clinical literature, limited randomized data, or credible human evidence that does not support broad claims.
2 - Low
Small human pharmacology studies, formulation-specific cosmetic studies, or indirect evidence.
1 - Very low
Mostly animal, cell, mechanistic, anecdotal, or vendor-driven claims without adequate human outcome data.
Editorial rules
What Does Not Raise a Grade
- Vendor certificates without clinical evidence
- Influencer anecdotes or before-and-after claims
- Animal models used as proof of human treatment benefits
- Biomarker changes used as a substitute for meaningful outcomes
- Claims that ignore FDA-approved versus research-only status